Loading...

Shire

DB:SP2
Snowflake Description

Fair value with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SP2
DB
£43B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The last earnings update was 76 days ago. More info.


Add to Portfolio Compare Print
SP2 Share Price and Events
7 Day Returns
0%
DB:SP2
-1.8%
DE Biotechs
0.4%
DE Market
1 Year Returns
31.5%
DB:SP2
-11.6%
DE Biotechs
-19.1%
DE Market
SP2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Shire (SP2) 0% 3.9% 1.5% 31.5% -4.2% 40.3%
DE Biotechs -1.8% -0.7% -7.5% -11.6% 33.3% -16.5%
DE Market 0.4% 0.1% -6.6% -19.1% 5.8% 0.6%
1 Year Return vs Industry and Market
  • SP2 outperformed the Biotechs industry which returned -11.6% over the past year.
  • SP2 outperformed the Market in Germany which returned -19.1% over the past year.
Price Volatility
SP2
Industry
5yr Volatility vs Market

Value

 Is Shire undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Shire to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Shire.

DB:SP2 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 19 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:SP2
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 9.8%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 0.85
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.852 (1 + (1- 12.5%) (28.16%))
1.061
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.06
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.061 * 9.77%)
10.6%

Discounted Cash Flow Calculation for DB:SP2 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Shire is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:SP2 DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (USD, Millions) 4,735.75 5,286.81 5,694.10 6,234.30 6,847.10
Source Analyst x5 Analyst x4 Analyst x2 Analyst x1 Analyst x1
Present Value
Discounted (@ 10.6%)
4,281.92 4,322.08 4,208.96 4,166.65 4,137.67
Present value of next 5 years cash flows $21,117.27
DB:SP2 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= $6,847.10 × (1 + 0.23%) ÷ (10.6% – 0.23%)
$66,173.70
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= $66,173.70 ÷ (1 + 10.6%)5
$39,988.42
DB:SP2 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= $21,117.27 + $39,988.42
$61,105.70
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $61,105.70 / 910.98
$67.08
DB:SP2 Discount to Share Price
Calculation Result
Exchange Rate USD/GBP
(Reporting currency to currency of LSE:SHP)
0.784
Value per Share
(GBP)
= Value per Share in USD x Exchange Rate (USD/GBP)
= $67.08 x 0.784
£52.58
Non-primary Listing Adjustment Factor 1 share in DB:SP2 represents 3.30918x of LSE:SHP
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
3.30918x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (GBP) x Listing Adjustment Factor
= £ 52.58 x 3.30918
€173.99
Value per share (EUR) From above. €173.99
Current discount Discount to share price of €155.20
= -1 x (€155.20 - €173.99) / €173.99
10.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Shire is available for.
Intrinsic value
11%
Share price is €155.2 vs Future cash flow value of €173.99
Current Discount Checks
For Shire to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Shire's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Shire's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Shire's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Shire's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:SP2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $5.28
LSE:SHP Share Price ** LSE (2019-01-04) in GBP £46.9
LSE:SHP Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.276 $59.83
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 27.36x
Germany Market PE Ratio Median Figure of 417 Publicly-Listed Companies 16.91x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Shire.

DB:SP2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= LSE:SHP Share Price ÷ EPS (both in USD)

= 59.83 ÷ 5.28

11.33x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Shire is good value based on earnings compared to the Europe Biotechs industry average.
  • Shire is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Shire's expected growth come at a high price?
Raw Data
DB:SP2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 11.33x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 19 Analysts
11.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 278 Publicly-Listed Companies 1.26x

*Line of best fit is calculated by linear regression .

DB:SP2 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 11.33x ÷ 11.1%

1.02x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Shire is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Shire's assets?
Raw Data
DB:SP2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $40.77
LSE:SHP Share Price * LSE (2019-01-04) in GBP £46.9
LSE:SHP Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.276 $59.83
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 2.44x
Germany Market PB Ratio Median Figure of 564 Publicly-Listed Companies 1.75x
DB:SP2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= LSE:SHP Share Price ÷ Book Value per Share (both in USD)

= 59.83 ÷ 40.77

1.47x

* Primary Listing of Shire.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Shire is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Shire's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Shire has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Shire expected to perform in the next 1 to 3 years based on estimates from 19 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Shire expected to grow at an attractive rate?
  • Shire's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Shire's earnings growth is expected to exceed the Germany market average.
  • Shire's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:SP2 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:SP2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 19 Analysts 11.1%
DB:SP2 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 19 Analysts 3.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 10.7%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 21.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10.3%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:SP2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 19 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:SP2 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 18,362 5,780 4
2022-12-31 17,389 6,860 4,647 8
2021-12-31 16,783 6,505 4,203 8
2020-12-31 16,298 6,028 3,929 15
2019-12-31 15,698 5,442 3,375 19
2018-12-31 15,539 4,820 2,560 18
DB:SP2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 15,702 4,327 4,809
2018-06-30 15,528 4,525 4,823
2018-03-31 15,354 4,808 4,449
2017-12-31 15,161 4,257 4,254
2017-09-30 14,822 3,890 1,623
2017-06-30 14,576 3,360 704
2017-03-31 13,260 2,729 549
2016-12-31 11,397 2,659 604
2016-09-30 9,306 2,268 411
2016-06-30 7,509 2,304 1,257
2016-03-31 6,638 2,165 1,334
2015-12-31 6,417 2,337 1,338

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Shire's earnings are expected to grow by 11.1% yearly, however this is not considered high growth (20% yearly).
  • Shire's revenue is expected to grow by 3.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:SP2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 19 Analyst Estimates (S&P Global) See Below

All data from Shire Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:SP2 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 5.73 5.73 5.73 1.00
2022-12-31 5.34 5.56 5.12 2.00
2021-12-31 4.81 5.02 4.59 2.00
2020-12-31 4.33 4.57 4.10 3.00
2019-12-31 3.63 3.92 3.44 5.00
2018-12-31 2.87 3.06 2.65 4.00
DB:SP2 Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 5.28
2018-06-30 5.30
2018-03-31 4.90
2017-12-31 4.69
2017-09-30 1.79
2017-06-30 0.78
2017-03-31 0.65
2016-12-31 0.78
2016-09-30 0.59
2016-06-30 2.05
2016-03-31 2.26
2015-12-31 2.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Shire is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Shire's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Shire has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Shire performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Shire's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Shire's year on year earnings growth rate has been positive over the past 5 years.
  • Shire's 1-year earnings growth exceeds its 5-year average (196.2% vs 17.3%)
  • Shire's earnings growth has exceeded the Europe Biotechs industry average in the past year (196.2% vs 22.6%).
Earnings and Revenue History
Shire's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Shire Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:SP2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 15,701.80 4,809.30 3,427.90 1,658.80
2018-06-30 15,527.70 4,823.30 3,452.30 1,654.40
2018-03-31 15,354.00 4,449.30 3,446.80 1,769.20
2017-12-31 15,160.60 4,253.50 3,530.90 1,743.30
2017-09-30 14,821.80 1,623.40 3,637.20 1,732.40
2017-06-30 14,576.30 703.70 3,653.10 1,840.70
2017-03-31 13,259.60 548.80 3,429.20 1,593.10
2016-12-31 11,396.60 603.50 3,015.20 1,430.90
2016-09-30 9,306.20 411.00 2,511.70 1,255.80
2016-06-30 7,509.10 1,256.60 2,078.40 985.90
2016-03-31 6,637.60 1,334.10 1,810.80 943.70
2015-12-31 6,416.70 1,337.50 1,842.50 920.30
2015-09-30 6,277.10 3,039.70 1,933.00 926.70
2015-06-30 6,219.20 3,078.40 2,013.60 914.10
2015-03-31 6,163.70 3,442.60 2,102.10 876.40
2014-12-31 6,022.10 3,282.80 1,782.00 877.20
2014-09-30 5,772.00 1,843.80 1,902.70 868.10
2014-06-30 5,387.60 1,629.10 1,776.10 865.70
2014-03-31 5,137.70 1,391.70 1,689.90 887.40
2013-12-31 4,934.30 1,419.60 1,651.30 913.50
2013-09-30 4,655.70 975.30 1,570.90 908.60
2013-06-30 4,543.40 901.40 1,612.00 907.10
2013-03-31 4,499.00 848.30 1,713.00 882.10
2012-12-31 4,527.40 805.70 1,821.30 881.80
2012-09-30 4,622.20 958.70 1,904.50 871.00
2012-06-30 4,607.90 924.40 1,919.20 831.80
2012-03-31 4,463.00 892.10 1,848.50 797.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Shire has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Shire used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Shire's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Shire's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Shire has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Shire's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Shire's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Shire's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Shire's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Shire's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Shire Company Filings, last reported 3 months ago.

DB:SP2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 37,290.20 15,346.70 193.20
2018-06-30 36,760.40 17,914.90 259.70
2018-03-31 37,400.00 18,520.90 317.70
2017-12-31 36,176.40 19,541.10 472.40
2017-09-30 32,654.60 20,585.20 209.30
2017-06-30 31,265.10 21,560.00 263.70
2017-03-31 29,731.90 22,545.40 369.00
2016-12-31 28,948.00 22,967.80 528.80
2016-09-30 29,785.70 24,075.70 728.60
2016-06-30 29,763.00 24,031.90 693.40
2016-03-31 10,294.70 6,865.30 69.00
2015-12-31 9,829.10 1,594.80 135.50
2015-09-30 9,553.80 2,076.40 44.90
2015-06-30 9,114.40 2,303.80 64.00
2015-03-31 8,980.70 2,648.90 74.30
2014-12-31 8,662.90 850.00 2,982.40
2014-09-30 6,538.30 850.03 467.70
2014-06-30 6,119.10 1,060.80 153.60
2014-03-31 5,645.80 1,521.30 139.10
2013-12-31 5,366.00 0.00 2,239.40
2013-09-30 4,168.80 1,100.00 1,686.10
2013-06-30 3,831.50 1,100.00 1,301.90
2013-03-31 3,782.10 1,100.00 1,450.70
2012-12-31 3,809.20 1,100.00 1,482.20
2012-09-30 3,878.00 1,100.00 1,321.90
2012-06-30 3,617.10 1,100.00 1,112.70
2012-03-31 3,520.60 1,100.00 879.40
  • Shire's level of debt (41.2%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (26% vs 41.2% today).
  • Debt is well covered by operating cash flow (28.2%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 8x coverage).
X
Financial health checks
We assess Shire's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Shire has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Shire's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.58%
Current annual income from Shire dividends. Estimated to be 0.82% next year.
If you bought €2,000 of Shire shares you are expected to receive €12 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Shire's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.6%).
  • Shire's dividend is below the markets top 25% of dividend payers in Germany (4%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:SP2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 19 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 328 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:SP2 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31 0.60 1.00
2022-12-31 0.64 2.00
2021-12-31 0.56 3.00
2020-12-31 0.50 7.00
2019-12-31 0.42 10.00
2018-12-31 0.39 6.00
DB:SP2 Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2018-02-14 0.349 0.643
2017-02-24 0.303 0.574
2016-02-23 0.264 0.441
2016-02-11 0.264 0.488
2015-07-23 0.233 0.338
2015-02-24 0.229 0.278
2015-02-12 0.229 0.291
2014-08-05 0.208 0.280
2014-02-13 0.199 0.333
2013-03-01 0.173 0.467
2012-08-01 0.153 0.502
2012-02-09 0.151 0.478
2011-07-28 0.133 0.414
2011-02-10 0.131 0.434
2010-08-04 0.112 0.484
2010-03-25 0.114 0.528
2010-02-26 0.114 0.516
2010-02-19 0.114 0.537
2009-08-05 0.099 0.545
2009-03-31 0.099 0.739
2009-01-19 0.086 0.669

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Shire is not paying a notable dividend for Germany, therefore no need to check if the payments are stable.
  • Shire is not paying a notable dividend for Germany, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Shire's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Shire's dividends as it is not paying a notable one for Germany.
Future Payout to shareholders
  • No need to calculate the sustainability of Shire's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Shire's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Shire afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Shire has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Shire's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Flemming Ornskov
COMPENSATION $4,135,346
AGE 60
TENURE AS CEO 5.8 years
CEO Bio

Dr. Flemming Ornskov, M.D., MBA, MPH, serves as Managing Director at Shire plc and also has been its Chief Executive Officer since April 30, 2013 and Executive Director since January 2, 2013. Dr. Ornskov brought to his role his operational and medical knowledge and his extensive international, strategic and operational experience in the pharmaceutical sector. Dr. Ornskov served as the Head of Human Genetic Therapies at Shire plc since March 31, 2013. He is currently a Non-Executive Director of the Swiss-American Chamber of Commerce and Waters Corporation since June 22, 2017. He served as the Chief Marketing Officer and Global Head of Strategic Marketing for General and Specialty Medicine at Bayer from 2010 to 2012. Prior to joining Bayer, he served as Global President of Pharmaceuticals and OTC at Bausch & Lomb, Inc. from 2008 to 2010. He also served as the Chairman and later as President and Chief Executive Officer of Life-Cycle Pharma A/S from 2006 to 2008 and President and Chief Executive Officer of Ikaria, Inc. from 2005 to 2006. In his pharmaceutical career, he held roles of increased responsibility at Merck & Co. Inc. and Novartis AG, following a distinguished period in hospital and academic medicine. He served as the Non-Executive Chairman at Evotec AG. He served as a Director at PCI Biotech Holding ASA from 2008 to January 2013. Dr. Ornskov received his MD from the University of Copenhagen, an MBA from INSEAD and a Master of Public Health from the Harvard University. He trained as an Intern and Resident in Pediatrics at the University Hospital of Copenhagen.

CEO Compensation
  • Flemming's compensation has been consistent with company performance over the past year.
  • Flemming's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Shire management team in years:

3.1
Average Tenure
54.5
Average Age
  • The tenure for the Shire management team is about average.
Management Team

Flemming Ornskov

TITLE
CEO, MD & Executive Director
COMPENSATION
$4M
AGE
60
TENURE
5.8 yrs

Thomas J. Dittrich

TITLE
CFO & Director
AGE
54
TENURE
0.8 yrs

Gisele Dion

TITLE
Chief Accounting Officer

Matt Walker

TITLE
Head of Technical Operations
AGE
54
TENURE
2.6 yrs

Andy Busch

TITLE
Head of Research & Development and Chief Scientific Officer
AGE
55
TENURE
1 yrs

Christoph Brackmann

TITLE
Interim Head of Investor Relations

Bill Mordan

TITLE
General Counsel & Corporate Secretary
AGE
48
TENURE
3.6 yrs

Jessica Mann

TITLE
Senior Vice President of Global Corporate Communications

John Neeley

TITLE
Head of Global Market Acesss

Joanne Cordeiro

TITLE
Chief Human Resources Officer
AGE
60
TENURE
8 yrs
Board of Directors Tenure

Average tenure and age of the Shire board of directors in years:

2.6
Average Tenure
60
Average Age
  • The average tenure for the Shire board of directors is less than 3 years, this suggests a new board.
Board of Directors

Susan Kilsby

TITLE
Non-Executive Chairman
COMPENSATION
$475K
AGE
59
TENURE
4.8 yrs

Flemming Ornskov

TITLE
CEO, MD & Executive Director
COMPENSATION
$4M
AGE
60
TENURE
6 yrs

Thomas J. Dittrich

TITLE
CFO & Director
AGE
54
TENURE
0.8 yrs

Sara Mathew

TITLE
Independent Non-Executive Director
COMPENSATION
$152K
AGE
63
TENURE
3.3 yrs

Al Stroucken

TITLE
Independent Non-Executive Director
COMPENSATION
$161K
AGE
70
TENURE
2.6 yrs

Olivier Bohuon

TITLE
Senior Independent Director
COMPENSATION
$136K
AGE
59
TENURE
0.8 yrs

Steve Gillis

TITLE
Independent Non-Executive Director
COMPENSATION
$158K
AGE
65
TENURE
6.3 yrs

Gail Fosler

TITLE
Independent Non-Executive Director
COMPENSATION
$132K
AGE
70
TENURE
2.6 yrs

Ian Clark

TITLE
Independent Non-Executive Director
COMPENSATION
$137K
AGE
58
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Jan 19 Sell State Street Global Advisors, Inc. Company 03. Jan 19 03. Jan 19 -4,996 €151.13 €-755,068
04. Jan 19 Sell Societe Generale Group, Banking Investments Company 03. Jan 19 03. Jan 19 -432 €150.92 €-65,199
04. Jan 19 Buy Societe Generale Group, Banking Investments Company 03. Jan 19 03. Jan 19 7,500 €151.62 €1,137,100
03. Jan 19 Buy Sachem Head Capital Management Company 02. Jan 19 02. Jan 19 137,000 €152.01 €20,825,739
03. Jan 19 Sell Societe Generale Group, Banking Investments Company 02. Jan 19 02. Jan 19 -90,000 €151.96 €-13,664,563
03. Jan 19 Buy Societe Generale Group, Banking Investments Company 02. Jan 19 02. Jan 19 45,000 €151.78 €6,827,736
02. Jan 19 Buy Societe Generale Group, Banking Investments Company 31. Dec 18 31. Dec 18 12,744 €152.22 €1,939,952
31. Dec 18 Sell Societe Generale Group, Banking Investments Company 28. Dec 18 28. Dec 18 -2,514 €151.13 €-379,775
31. Dec 18 Buy Societe Generale Group, Banking Investments Company 28. Dec 18 28. Dec 18 30,000 €151.37 €4,539,907
28. Dec 18 Sell State Street Global Advisors, Inc. Company 27. Dec 18 27. Dec 18 -136 €151.37 €-20,587
27. Dec 18 Sell Societe Generale Group, Banking Investments Company 24. Dec 18 24. Dec 18 -21 €148.21 €-3,112
27. Dec 18 Buy Societe Generale Group, Banking Investments Company 24. Dec 18 24. Dec 18 7,374 €148.21 €1,092,877
27. Dec 18 Sell State Street Global Advisors, Inc. Company 21. Dec 18 21. Dec 18 -21,000 €148.98 €-3,128,586
24. Dec 18 Sell Societe Generale Group, Banking Investments Company 21. Dec 18 21. Dec 18 -99,345 €150.56 €-14,957,217
24. Dec 18 Buy Societe Generale Group, Banking Investments Company 21. Dec 18 21. Dec 18 37,782 €150.04 €5,668,830
21. Dec 18 Buy Societe Generale Group, Banking Investments Company 20. Dec 18 20. Dec 18 64,161 €150.83 €9,677,402
20. Dec 18 Sell Societe Generale Group, Banking Investments Company 19. Dec 18 19. Dec 18 -61,995 €147.75 €-9,159,840
20. Dec 18 Buy Societe Generale Group, Banking Investments Company 19. Dec 18 19. Dec 18 93,630 €147.71 €13,829,854
20. Dec 18 Sell D. E. Shaw & Co., L.P. Company 19. Dec 18 19. Dec 18 -12,900 €147.71 €0
19. Dec 18 Sell Societe Generale Group, Banking Investments Company 18. Dec 18 18. Dec 18 -26,550 €146.79 €-3,897,397
19. Dec 18 Buy Societe Generale Group, Banking Investments Company 18. Dec 18 18. Dec 18 50,319 €146.47 €7,370,179
18. Dec 18 Sell D. E. Shaw & Co., L.P. Company 17. Dec 18 17. Dec 18 -9,900 €150.36 €-1,488,539
18. Dec 18 Sell Societe Generale Group, Banking Investments Company 17. Dec 18 17. Dec 18 -39,750 €151.22 €-6,011,048
18. Dec 18 Buy Societe Generale Group, Banking Investments Company 17. Dec 18 17. Dec 18 20,397 €150.90 €3,077,809
17. Dec 18 Sell Societe Generale Group, Banking Investments Company 14. Dec 18 14. Dec 18 -79,494 €156.21 €-12,417,615
17. Dec 18 Buy Societe Generale Group, Banking Investments Company 14. Dec 18 14. Dec 18 12,333 €155.90 €1,922,730
14. Dec 18 Sell Societe Generale Group, Banking Investments Company 13. Dec 18 13. Dec 18 -21,243 €155.66 €-3,306,765
14. Dec 18 Buy Societe Generale Group, Banking Investments Company 13. Dec 18 13. Dec 18 24,291 €155.65 €3,780,800
13. Dec 18 Sell Societe Generale Group, Banking Investments Company 12. Dec 18 12. Dec 18 -111,867 €152.05 €-17,008,865
13. Dec 18 Buy Societe Generale Group, Banking Investments Company 12. Dec 18 12. Dec 18 28,125 €151.88 €4,271,573
12. Dec 18 Sell Societe Generale Group, Banking Investments Company 11. Dec 18 11. Dec 18 -28,137 €150.55 €-4,236,050
12. Dec 18 Buy Societe Generale Group, Banking Investments Company 11. Dec 18 11. Dec 18 38,697 €150.53 €5,825,184
11. Dec 18 Sell Societe Generale Group, Banking Investments Company 10. Dec 18 10. Dec 18 -26,634 €150.07 €-3,996,912
11. Dec 18 Buy Societe Generale Group, Banking Investments Company 10. Dec 18 10. Dec 18 68,052 €150.38 €10,233,532
10. Dec 18 Sell Societe Generale Group, Banking Investments Company 07. Dec 18 07. Dec 18 -179,709 €153.05 €-27,505,119
10. Dec 18 Buy Societe Generale Group, Banking Investments Company 07. Dec 18 07. Dec 18 110,151 €152.25 €16,770,060
07. Dec 18 Sell Societe Generale Group, Banking Investments Company 06. Dec 18 06. Dec 18 -48,768 €156.75 €-7,644,533
07. Dec 18 Buy Societe Generale Group, Banking Investments Company 06. Dec 18 06. Dec 18 174,570 €156.65 €27,345,958
05. Dec 18 Sell State Street Global Advisors, Inc. Company 04. Dec 18 04. Dec 18 -1,087 €152.52 €-165,790
05. Dec 18 Buy D. E. Shaw & Co., L.P. Company 04. Dec 18 04. Dec 18 20,000 €153.84 €3,076,814
05. Dec 18 Sell Societe Generale Group, Banking Investments Company 04. Dec 18 04. Dec 18 -53,358 €153.73 €-8,202,935
05. Dec 18 Buy Societe Generale Group, Banking Investments Company 04. Dec 18 04. Dec 18 30,861 €153.68 €4,742,785
04. Dec 18 Buy D. E. Shaw & Co., L.P. Company 03. Dec 18 03. Dec 18 30,000 €155.00 €4,650,096
03. Dec 18 Sell Societe Generale Group, Banking Investments Company 30. Nov 18 30. Nov 18 -7,485 €154.69 €-1,157,873
03. Dec 18 Buy Societe Generale Group, Banking Investments Company 30. Nov 18 30. Nov 18 21,960 €155.25 €3,409,242
03. Dec 18 Buy D. E. Shaw & Co., L.P. Company 30. Nov 18 30. Nov 18 26,593 €155.54 €4,136,285
30. Nov 18 Sell Societe Generale Group, Banking Investments Company 29. Nov 18 29. Nov 18 -19,743 €152.44 €-3,009,643
30. Nov 18 Buy Societe Generale Group, Banking Investments Company 29. Nov 18 29. Nov 18 15,396 €151.68 €2,335,215
29. Nov 18 Buy D. E. Shaw & Co., L.P. Company 28. Nov 18 28. Nov 18 9,989 €153.34 €1,529,829
29. Nov 18 Sell Societe Generale Group, Banking Investments Company 28. Nov 18 28. Nov 18 -24,432 €153.35 €-3,746,589
29. Nov 18 Buy Societe Generale Group, Banking Investments Company 28. Nov 18 28. Nov 18 30,555 €153.32 €4,684,724
28. Nov 18 Sell Societe Generale Group, Banking Investments Company 27. Nov 18 27. Nov 18 -6,162 €154.10 €-949,569
28. Nov 18 Buy Societe Generale Group, Banking Investments Company 27. Nov 18 27. Nov 18 20,565 €153.89 €3,164,835
27. Nov 18 Sell Societe Generale Group, Banking Investments Company 26. Nov 18 26. Nov 18 -4,929 €156.83 €-773,006
27. Nov 18 Buy Societe Generale Group, Banking Investments Company 26. Nov 18 26. Nov 18 15,612 €156.83 €2,448,401
26. Nov 18 Sell Societe Generale Group, Banking Investments Company 23. Nov 18 23. Nov 18 -17,184 €156.13 €-2,682,967
26. Nov 18 Buy Societe Generale Group, Banking Investments Company 23. Nov 18 23. Nov 18 13,119 €156.13 €2,048,292
26. Nov 18 Sell State Street Global Advisors, Inc. Company 23. Nov 18 23. Nov 18 -200 €155.44 €-31,088
22. Nov 18 Sell Societe Generale Group, Banking Investments Company 21. Nov 18 21. Nov 18 -13,752 €155.26 €-2,135,198
22. Nov 18 Buy Societe Generale Group, Banking Investments Company 21. Nov 18 21. Nov 18 38,301 €155.26 €5,946,788
21. Nov 18 Sell Societe Generale Group, Banking Investments Company 20. Nov 18 20. Nov 18 -41,961 €156.30 €-6,558,561
21. Nov 18 Buy Societe Generale Group, Banking Investments Company 20. Nov 18 20. Nov 18 29,358 €156.55 €4,596,135
20. Nov 18 Sell Societe Generale Group, Banking Investments Company 19. Nov 18 19. Nov 18 -28,734 €155.11 €-4,456,822
20. Nov 18 Buy Societe Generale Group, Banking Investments Company 19. Nov 18 19. Nov 18 40,146 €154.73 €6,211,920
20. Nov 18 Buy D. E. Shaw & Co., L.P. Company 19. Nov 18 19. Nov 18 50,000 €155.30 €7,764,915
19. Nov 18 Buy D. E. Shaw & Co., L.P. Company 16. Nov 18 16. Nov 18 28,768 €154.77 €4,452,505
19. Nov 18 Sell Societe Generale Group, Banking Investments Company 16. Nov 18 16. Nov 18 -13,983 €154.44 €-2,159,580
19. Nov 18 Buy Societe Generale Group, Banking Investments Company 16. Nov 18 16. Nov 18 15,273 €154.34 €2,357,252
16. Nov 18 Sell Societe Generale Group, Banking Investments Company 15. Nov 18 15. Nov 18 -13,143 €158.24 €-2,079,693
16. Nov 18 Buy Societe Generale Group, Banking Investments Company 15. Nov 18 15. Nov 18 72,528 €158.21 €11,474,601
16. Nov 18 Sell D. E. Shaw & Co., L.P. Company 15. Nov 18 15. Nov 18 -200 €156.62 €-31,324
16. Nov 18 Buy D. E. Shaw & Co., L.P. Company 15. Nov 18 15. Nov 18 23,998 €156.89 €3,765,100
15. Nov 18 Buy D. E. Shaw & Co., L.P. Company 14. Nov 18 14. Nov 18 35,466 €160.36 €5,687,490
15. Nov 18 Sell Societe Generale Group, Banking Investments Company 14. Nov 18 14. Nov 18 -25,719 €159.96 €-4,113,963
15. Nov 18 Buy Societe Generale Group, Banking Investments Company 14. Nov 18 14. Nov 18 26,088 €159.93 €4,172,296
15. Nov 18 Buy Adage Capital Management, L.P. Company 14. Nov 18 14. Nov 18 75,000 €158.27 €11,870,282
14. Nov 18 Buy State Street Global Advisors, Inc. Company 13. Nov 18 13. Nov 18 2,400 €160.26 €384,624
14. Nov 18 Buy Societe Generale Group, Banking Investments Company 13. Nov 18 13. Nov 18 24,033 €160.30 €3,852,460
13. Nov 18 Sell Societe Generale Group, Banking Investments Company 12. Nov 18 12. Nov 18 -13,344 €161.93 €-2,160,785
13. Nov 18 Buy Societe Generale Group, Banking Investments Company 12. Nov 18 12. Nov 18 114,465 €161.75 €18,515,120
13. Nov 18 Buy Adage Capital Management, L.P. Company 12. Nov 18 12. Nov 18 300,000 €161.58 €48,475,392
12. Nov 18 Sell Societe Generale Group, Banking Investments Company 09. Nov 18 09. Nov 18 -43,014 €159.26 €-6,850,491
12. Nov 18 Buy Societe Generale Group, Banking Investments Company 09. Nov 18 09. Nov 18 11,388 €159.00 €1,810,662
09. Nov 18 Buy Adage Capital Management, L.P. Company 08. Nov 18 08. Nov 18 700,000 €158.29 €110,804,464
09. Nov 18 Sell Societe Generale Group, Banking Investments Company 08. Nov 18 08. Nov 18 -22,338 €158.57 €-3,542,189
09. Nov 18 Buy Societe Generale Group, Banking Investments Company 08. Nov 18 08. Nov 18 10,203 €158.48 €1,616,931
09. Nov 18 Buy D. E. Shaw & Co., L.P. Company 08. Nov 18 08. Nov 18 50,949 €158.68 €8,084,457
08. Nov 18 Buy D. E. Shaw & Co., L.P. Company 07. Nov 18 07. Nov 18 60,000 €158.33 €9,500,091
08. Nov 18 Sell Societe Generale Group, Banking Investments Company 07. Nov 18 07. Nov 18 -21,039 €157.73 €-3,318,554
08. Nov 18 Buy Societe Generale Group, Banking Investments Company 07. Nov 18 07. Nov 18 17,835 €157.98 €2,817,529
07. Nov 18 Sell Societe Generale Group, Banking Investments Company 06. Nov 18 06. Nov 18 -11,046 €156.97 €-1,733,904
07. Nov 18 Buy Societe Generale Group, Banking Investments Company 06. Nov 18 06. Nov 18 12,384 €157.01 €1,944,366
07. Nov 18 Buy D. E. Shaw & Co., L.P. Company 06. Nov 18 06. Nov 18 10,369 €156.84 €1,626,272
07. Nov 18 Buy Adage Capital Management, L.P. Company 06. Nov 18 06. Nov 18 137,389 €156.86 €21,550,471
06. Nov 18 Sell Societe Generale Group, Banking Investments Company 05. Nov 18 05. Nov 18 -7,824 €156.96 €-1,228,029
06. Nov 18 Buy Societe Generale Group, Banking Investments Company 05. Nov 18 05. Nov 18 7,494 €156.96 €1,176,233
06. Nov 18 Buy D. E. Shaw & Co., L.P. Company 05. Nov 18 05. Nov 18 25,817 €156.98 €4,052,830
05. Nov 18 Buy Adage Capital Management, L.P. Company 02. Nov 18 02. Nov 18 45,969 €155.92 €7,167,706
05. Nov 18 Buy D. E. Shaw & Co., L.P. Company 02. Nov 18 02. Nov 18 22,000 €156.89 €3,451,603
05. Nov 18 Sell Societe Generale Group, Banking Investments Company 02. Nov 18 02. Nov 18 -27,066 €155.99 €-4,221,924
05. Nov 18 Buy Societe Generale Group, Banking Investments Company 02. Nov 18 02. Nov 18 10,638 €156.60 €1,665,906
02. Nov 18 Sell Societe Generale Group, Banking Investments Company 01. Nov 18 01. Nov 18 -7,083 €158.81 €-1,124,859
02. Nov 18 Buy Societe Generale Group, Banking Investments Company 01. Nov 18 01. Nov 18 20,592 €158.81 €3,270,237
02. Nov 18 Buy D. E. Shaw & Co., L.P. Company 01. Nov 18 01. Nov 18 33,700 €158.71 €5,348,678
01. Nov 18 Buy D. E. Shaw & Co., L.P. Company 31. Oct 18 31. Oct 18 33,721 €157.62 €5,314,983
01. Nov 18 Sell Societe Generale Group, Banking Investments Company 31. Oct 18 31. Oct 18 -14,163 €160.62 €-2,274,865
01. Nov 18 Buy Societe Generale Group, Banking Investments Company 31. Oct 18 31. Oct 18 8,634 €160.62 €1,386,796
31. Oct 18 Sell Societe Generale Group, Banking Investments Company 30. Oct 18 30. Oct 18 -41,271 €155.92 €-6,434,913
31. Oct 18 Buy Societe Generale Group, Banking Investments Company 30. Oct 18 30. Oct 18 23,370 €155.92 €3,643,816
31. Oct 18 Sell Standard Life Aberdeen plc Company 30. Oct 18 30. Oct 18 -26,400 €154.35 €-4,074,821
31. Oct 18 Buy D. E. Shaw & Co., L.P. Company 30. Oct 18 30. Oct 18 65,000 €154.61 €10,049,466
30. Oct 18 Buy D. E. Shaw & Co., L.P. Company 29. Oct 18 29. Oct 18 65,000 €153.09 €9,950,682
30. Oct 18 Sell Societe Generale Group, Banking Investments Company 29. Oct 18 29. Oct 18 -89,925 €153.65 €-13,816,945
30. Oct 18 Buy Societe Generale Group, Banking Investments Company 29. Oct 18 29. Oct 18 35,943 €153.65 €5,522,629
29. Oct 18 Buy D. E. Shaw & Co., L.P. Company 26. Oct 18 26. Oct 18 46,991 €149.66 €7,032,732
29. Oct 18 Buy Adage Capital Management, L.P. Company 26. Oct 18 26. Oct 18 166,642 €148.35 €24,721,723
29. Oct 18 Sell Societe Generale Group, Banking Investments Company 26. Oct 18 26. Oct 18 -41,895 €149.13 €-6,247,608
29. Oct 18 Buy Societe Generale Group, Banking Investments Company 26. Oct 18 26. Oct 18 25,563 €148.69 €3,800,863
26. Oct 18 Sell Societe Generale Group, Banking Investments Company 25. Oct 18 25. Oct 18 -22,959 €150.27 €-3,450,103
26. Oct 18 Buy Societe Generale Group, Banking Investments Company 25. Oct 18 25. Oct 18 45,747 €150.37 €6,879,136
26. Oct 18 Buy D. E. Shaw & Co., L.P. Company 25. Oct 18 25. Oct 18 30,000 €150.42 €4,512,656
25. Oct 18 Buy D. E. Shaw & Co., L.P. Company 24. Oct 18 24. Oct 18 30,000 €153.40 €4,601,871
25. Oct 18 Sell Societe Generale Group, Banking Investments Company 24. Oct 18 24. Oct 18 -20,565 €151.91 €-3,124,069
25. Oct 18 Buy Societe Generale Group, Banking Investments Company 24. Oct 18 24. Oct 18 12,177 €152.50 €1,856,999
24. Oct 18 Sell Societe Generale Group, Banking Investments Company 23. Oct 18 23. Oct 18 -17,058 €153.39 €-2,616,554
24. Oct 18 Buy Societe Generale Group, Banking Investments Company 23. Oct 18 23. Oct 18 26,241 €153.39 €4,025,149
23. Oct 18 Sell Societe Generale Group, Banking Investments Company 22. Oct 18 22. Oct 18 -5,943 €153.77 €-913,839
23. Oct 18 Buy Societe Generale Group, Banking Investments Company 22. Oct 18 22. Oct 18 43,965 €154.02 €0
22. Oct 18 Sell Societe Generale Group, Banking Investments Company 19. Oct 18 19. Oct 18 -4,452 €154.05 €-685,842
22. Oct 18 Buy Societe Generale Group, Banking Investments Company 19. Oct 18 19. Oct 18 5,859 €154.01 €902,340
19. Oct 18 Sell Societe Generale Group, Banking Investments Company 18. Oct 18 18. Oct 18 -24,288 €154.61 €-3,755,267
19. Oct 18 Buy Societe Generale Group, Banking Investments Company 18. Oct 18 18. Oct 18 4,698 €154.37 €725,233
18. Oct 18 Sell Societe Generale Group, Banking Investments Company 17. Oct 18 17. Oct 18 -17,322 €153.74 €-2,663,074
18. Oct 18 Buy Societe Generale Group, Banking Investments Company 17. Oct 18 17. Oct 18 2,760 €153.72 €424,260
17. Oct 18 Sell Societe Generale Group, Banking Investments Company 16. Oct 18 16. Oct 18 -15,546 €151.69 €-2,358,222
17. Oct 18 Buy Societe Generale Group, Banking Investments Company 16. Oct 18 16. Oct 18 26,631 €151.45 €4,033,256
16. Oct 18 Sell Societe Generale Group, Banking Investments Company 15. Oct 18 15. Oct 18 -6,819 €148.76 €-1,014,422
16. Oct 18 Buy Societe Generale Group, Banking Investments Company 15. Oct 18 15. Oct 18 29,223 €148.62 €4,343,043
15. Oct 18 Sell State Street Global Advisors, Inc. Company 12. Oct 18 12. Oct 18 -21 €146.70 €-3,081
15. Oct 18 Sell Societe Generale Group, Banking Investments Company 12. Oct 18 12. Oct 18 -7,923 €147.64 €-1,169,730
15. Oct 18 Buy Societe Generale Group, Banking Investments Company 12. Oct 18 12. Oct 18 11,394 €147.47 €1,680,305
12. Oct 18 Sell Societe Generale Group, Banking Investments Company 11. Oct 18 11. Oct 18 -12,273 €147.12 €-1,805,545
12. Oct 18 Buy Societe Generale Group, Banking Investments Company 11. Oct 18 11. Oct 18 13,641 €148.04 €2,019,482
11. Oct 18 Sell Societe Generale Group, Banking Investments Company 10. Oct 18 10. Oct 18 -39,627 €150.46 €-5,962,247
11. Oct 18 Buy Societe Generale Group, Banking Investments Company 10. Oct 18 10. Oct 18 8,388 €150.47 €1,262,125
10. Oct 18 Sell Societe Generale Group, Banking Investments Company 09. Oct 18 09. Oct 18 -6,936 €151.14 €-1,048,277
10. Oct 18 Buy Societe Generale Group, Banking Investments Company 09. Oct 18 09. Oct 18 8,409 €151.05 €1,270,167
09. Oct 18 Sell Societe Generale Group, Banking Investments Company 08. Oct 18 08. Oct 18 -9,126 €150.68 €-1,375,127
09. Oct 18 Buy Societe Generale Group, Banking Investments Company 08. Oct 18 08. Oct 18 56,619 €150.63 €8,528,523
08. Oct 18 Sell Societe Generale Group, Banking Investments Company 05. Oct 18 05. Oct 18 -25,086 €151.30 €-3,795,526
08. Oct 18 Buy Societe Generale Group, Banking Investments Company 05. Oct 18 05. Oct 18 8,595 €152.13 €1,307,531
05. Oct 18 Sell Societe Generale Group, Banking Investments Company 04. Oct 18 04. Oct 18 -31,296 €154.10 €-4,822,638
05. Oct 18 Buy Societe Generale Group, Banking Investments Company 04. Oct 18 04. Oct 18 9,738 €153.69 €1,496,656
04. Oct 18 Sell Societe Generale Group, Banking Investments Company 03. Oct 18 03. Oct 18 -3,360 €156.83 €-526,934
04. Oct 18 Buy Societe Generale Group, Banking Investments Company 03. Oct 18 03. Oct 18 4,182 €156.74 €655,472
03. Oct 18 Sell Societe Generale Group, Banking Investments Company 02. Oct 18 02. Oct 18 -1,125 €154.83 €-174,188
03. Oct 18 Buy Societe Generale Group, Banking Investments Company 02. Oct 18 02. Oct 18 4,470 €154.94 €692,574
02. Oct 18 Sell Societe Generale Group, Banking Investments Company 01. Oct 18 01. Oct 18 -4,116 €154.65 €-636,529
02. Oct 18 Buy Societe Generale Group, Banking Investments Company 01. Oct 18 01. Oct 18 31,644 €154.51 €4,889,248
01. Oct 18 Sell Societe Generale Group, Banking Investments Company 28. Sep 18 28. Sep 18 -10,596 €156.51 €-1,658,422
01. Oct 18 Buy Societe Generale Group, Banking Investments Company 28. Sep 18 28. Sep 18 1,626 €156.14 €253,883
28. Sep 18 Sell Societe Generale Group, Banking Investments Company 27. Sep 18 27. Sep 18 -522 €155.95 €-81,408
28. Sep 18 Buy Societe Generale Group, Banking Investments Company 27. Sep 18 27. Sep 18 22,278 €155.99 €3,475,123
27. Sep 18 Sell Societe Generale Group, Banking Investments Company 26. Sep 18 26. Sep 18 -4,077 €153.81 €-627,087
27. Sep 18 Buy Societe Generale Group, Banking Investments Company 26. Sep 18 26. Sep 18 51,177 €154.31 €7,897,003
26. Sep 18 Sell Societe Generale Group, Banking Investments Company 25. Sep 18 25. Sep 18 -10,610 €151.81 €-1,610,748
26. Sep 18 Buy Societe Generale Group, Banking Investments Company 25. Sep 18 25. Sep 18 13,541 €151.77 €2,055,140
25. Sep 18 Sell State Street Global Advisors, Inc. Company 24. Sep 18 24. Sep 18 -1,265 €150.58 €-190,481
25. Sep 18 Sell Societe Generale Group, Banking Investments Company 24. Sep 18 24. Sep 18 -23,667 €151.44 €-3,584,019
25. Sep 18 Buy Societe Generale Group, Banking Investments Company 24. Sep 18 24. Sep 18 23,451 €151.06 €3,542,549
24. Sep 18 Sell Societe Generale Group, Banking Investments Company 21. Sep 18 21. Sep 18 -4,185 €152.44 €-637,964
24. Sep 18 Buy Societe Generale Group, Banking Investments Company 21. Sep 18 21. Sep 18 17,052 €152.51 €2,600,577
21. Sep 18 Sell Societe Generale Group, Banking Investments Company 20. Sep 18 20. Sep 18 -564 €153.49 €-86,567
21. Sep 18 Buy Societe Generale Group, Banking Investments Company 20. Sep 18 20. Sep 18 5,781 €153.20 €885,638
19. Sep 18 Sell Societe Generale Group, Banking Investments Company 18. Sep 18 18. Sep 18 -8,916 €152.44 €-1,359,181
19. Sep 18 Buy Societe Generale Group, Banking Investments Company 18. Sep 18 18. Sep 18 5,517 €152.44 €841,028
18. Sep 18 Sell Societe Generale Group, Banking Investments Company 17. Sep 18 17. Sep 18 -792 €151.22 €-119,766
18. Sep 18 Buy Societe Generale Group, Banking Investments Company 17. Sep 18 17. Sep 18 8,664 €151.36 €1,311,350
17. Sep 18 Buy Societe Generale Group, Banking Investments Company 14. Sep 18 14. Sep 18 3,981 €152.07 €605,387
14. Sep 18 Sell Societe Generale Group, Banking Investments Company 13. Sep 18 13. Sep 18 -1,878 €147.61 €-277,215
14. Sep 18 Buy Societe Generale Group, Banking Investments Company 13. Sep 18 13. Sep 18 30,564 €147.72 €4,515,039
13. Sep 18 Sell Societe Generale Group, Banking Investments Company 12. Sep 18 12. Sep 18 -7,686 €148.44 €-1,140,874
13. Sep 18 Buy Societe Generale Group, Banking Investments Company 12. Sep 18 12. Sep 18 6,975 €148.55 €1,036,116
12. Sep 18 Sell State Street Global Advisors, Inc. Company 11. Sep 18 11. Sep 18 -12,202 €146.89 €-1,792,370
12. Sep 18 Sell Societe Generale Group, Banking Investments Company 11. Sep 18 11. Sep 18 -12,750 €146.94 €-1,873,545
12. Sep 18 Buy Societe Generale Group, Banking Investments Company 11. Sep 18 11. Sep 18 5,730 €146.89 €841,688
11. Sep 18 Buy Adage Capital Management, L.P. Company 10. Sep 18 10. Sep 18 46,481 €143.64 €6,676,433
11. Sep 18 Sell Societe Generale Group, Banking Investments Company 10. Sep 18 10. Sep 18 -6,630 €144.71 €-959,459
11. Sep 18 Buy Societe Generale Group, Banking Investments Company 10. Sep 18 10. Sep 18 9,300 €144.72 €1,345,927
10. Sep 18 Buy Adage Capital Management, L.P. Company 07. Sep 18 07. Sep 18 29,300 €143.45 €4,203,161
10. Sep 18 Sell Societe Generale Group, Banking Investments Company 07. Sep 18 07. Sep 18 -20,793 €144.47 €-3,003,873
10. Sep 18 Buy Societe Generale Group, Banking Investments Company 07. Sep 18 07. Sep 18 3,828 €144.28 €552,304
07. Sep 18 Sell Societe Generale Group, Banking Investments Company 06. Sep 18 06. Sep 18 -20,532 €144.89 €-2,974,790
07. Sep 18 Buy Societe Generale Group, Banking Investments Company 06. Sep 18 06. Sep 18 4,584 €144.75 €663,556
06. Sep 18 Sell Societe Generale Group, Banking Investments Company 05. Sep 18 05. Sep 18 -19,077 €147.23 €-2,808,723
06. Sep 18 Buy Societe Generale Group, Banking Investments Company 05. Sep 18 05. Sep 18 11,691 €147.39 €1,723,189
05. Sep 18 Sell Societe Generale Group, Banking Investments Company 04. Sep 18 04. Sep 18 -5,058 €149.63 €-756,834
05. Sep 18 Buy Societe Generale Group, Banking Investments Company 04. Sep 18 04. Sep 18 6,447 €149.73 €965,329
03. Sep 18 Sell Societe Generale Group, Banking Investments Company 31. Aug 18 31. Aug 18 -8,724 €151.04 €-1,317,657
03. Sep 18 Buy Societe Generale Group, Banking Investments Company 31. Aug 18 31. Aug 18 2,232 €151.00 €337,021
31. Aug 18 Sell Societe Generale Group, Banking Investments Company 30. Aug 18 30. Aug 18 -2,115 €151.06 €-319,499
31. Aug 18 Buy Societe Generale Group, Banking Investments Company 30. Aug 18 30. Aug 18 6,648 €151.12 €1,004,660
30. Aug 18 Sell Societe Generale Group, Banking Investments Company 29. Aug 18 29. Aug 18 -5,178 €151.19 €-782,860
30. Aug 18 Buy Societe Generale Group, Banking Investments Company 29. Aug 18 29. Aug 18 3,507 €151.33 €530,702
28. Aug 18 Sell State Street Global Advisors, Inc. Company 24. Aug 18 24. Aug 18 -241 €149.91 €-36,120
28. Aug 18 Sell Societe Generale Group, Banking Investments Company 24. Aug 18 24. Aug 18 -6,702 €149.93 €-1,004,854
28. Aug 18 Buy Societe Generale Group, Banking Investments Company 24. Aug 18 24. Aug 18 3,795 €149.95 €569,063
23. Aug 18 Sell Societe Generale Group, Banking Investments Company 22. Aug 18 22. Aug 18 -6,936 €148.35 €-1,028,941
23. Aug 18 Buy Societe Generale Group, Banking Investments Company 22. Aug 18 22. Aug 18 4,683 €148.23 €694,155
22. Aug 18 Sell Societe Generale Group, Banking Investments Company 21. Aug 18 21. Aug 18 -615 €148.78 €-91,503
22. Aug 18 Buy Societe Generale Group, Banking Investments Company 21. Aug 18 21. Aug 18 9,297 €148.73 €1,382,768
21. Aug 18 Sell Societe Generale Group, Banking Investments Company 20. Aug 18 20. Aug 18 -12,456 €149.70 €-1,864,651
21. Aug 18 Buy Societe Generale Group, Banking Investments Company 20. Aug 18 20. Aug 18 19,899 €150.12 €2,987,192
20. Aug 18 Sell Societe Generale Group, Banking Investments Company 17. Aug 18 17. Aug 18 -18,630 €149.32 €-2,781,869
20. Aug 18 Buy Societe Generale Group, Banking Investments Company 17. Aug 18 17. Aug 18 11,394 €149.32 €1,701,375
16. Aug 18 Sell Societe Generale Group, Banking Investments Company 15. Aug 18 15. Aug 18 -14,871 €148.87 €-2,213,866
16. Aug 18 Buy Societe Generale Group, Banking Investments Company 15. Aug 18 15. Aug 18 4,197 €148.69 €624,035
15. Aug 18 Sell Societe Generale Group, Banking Investments Company 14. Aug 18 14. Aug 18 -2,808 €149.46 €-419,673
15. Aug 18 Buy Societe Generale Group, Banking Investments Company 14. Aug 18 14. Aug 18 38,589 €149.16 €5,755,845
14. Aug 18 Sell Societe Generale Group, Banking Investments Company 13. Aug 18 13. Aug 18 -1,932 €149.48 €-288,786
14. Aug 18 Buy Societe Generale Group, Banking Investments Company 13. Aug 18 13. Aug 18 3,825 €149.28 €570,996
13. Aug 18 Sell Societe Generale Group, Banking Investments Company 10. Aug 18 10. Aug 18 -15,111 €150.31 €-2,271,383
13. Aug 18 Buy Societe Generale Group, Banking Investments Company 10. Aug 18 10. Aug 18 15,183 €150.31 €2,282,205
08. Aug 18 Sell Societe Generale Group, Banking Investments Company 07. Aug 18 07. Aug 18 -654 €150.02 €-98,115
08. Aug 18 Buy Societe Generale Group, Banking Investments Company 07. Aug 18 07. Aug 18 5,616 €149.99 €842,344
07. Aug 18 Sell Societe Generale Group, Banking Investments Company 06. Aug 18 06. Aug 18 -12,135 €149.81 €-1,817,934
07. Aug 18 Buy Societe Generale Group, Banking Investments Company 06. Aug 18 06. Aug 18 7,515 €149.69 €1,124,906
18. Jun 18 Sell State Street Global Advisors, Inc. Company 15. Jun 18 15. Jun 18 -1,300 €139.17 €-180,921
06. Aug 18 Sell Societe Generale Group, Banking Investments Company 03. Aug 18 03. Aug 18 -2,814 €149.16 €-419,738
06. Aug 18 Buy Societe Generale Group, Banking Investments Company 03. Aug 18 03. Aug 18 3,735 €149.74 €559,272
03. Aug 18 Sell Societe Generale Group, Banking Investments Company 01. Aug 18 01. Aug 18 -13,500 €150.50 €-2,031,720
03. Aug 18 Buy Societe Generale Group, Banking Investments Company 01. Aug 18 01. Aug 18 4,536 €150.50 €682,658
01. Aug 18 Sell Societe Generale Group, Banking Investments Company 31. Jul 18 31. Jul 18 -6,849 €146.56 €-1,003,786
01. Aug 18 Buy Societe Generale Group, Banking Investments Company 31. Jul 18 31. Jul 18 3,120 €146.73 €457,786
31. Jul 18 Sell Societe Generale Group, Banking Investments Company 30. Jul 18 30. Jul 18 -5,997 €145.45 €-872,284
31. Jul 18 Buy Societe Generale Group, Banking Investments Company 30. Jul 18 30. Jul 18 2,364 €145.64 €344,286
30. Jul 18 Sell Societe Generale Group, Banking Investments Company 27. Jul 18 27. Jul 18 -20,844 €147.20 €-3,068,294
30. Jul 18 Buy Societe Generale Group, Banking Investments Company 27. Jul 18 27. Jul 18 9,222 €147.61 €1,361,279
27. Jul 18 Sell Societe Generale Group, Banking Investments Company 26. Jul 18 26. Jul 18 -11,433 €147.71 €-1,688,801
27. Jul 18 Buy Societe Generale Group, Banking Investments Company 26. Jul 18 26. Jul 18 3,870 €147.69 €571,568
26. Jul 18 Sell Societe Generale Group, Banking Investments Company 25. Jul 18 25. Jul 18 -657 €147.74 €-97,064
26. Jul 18 Buy Societe Generale Group, Banking Investments Company 25. Jul 18 25. Jul 18 15,156 €147.73 €2,239,039
25. Jul 18 Sell Societe Generale Group, Banking Investments Company 24. Jul 18 24. Jul 18 -2,148 €147.72 €-317,300
25. Jul 18 Buy Societe Generale Group, Banking Investments Company 24. Jul 18 24. Jul 18 13,041 €147.72 €1,926,400
24. Jul 18 Sell Societe Generale Group, Banking Investments Company 23. Jul 18 23. Jul 18 -470,436 €146.33 €-68,840,370
24. Jul 18 Buy Societe Generale Group, Banking Investments Company 23. Jul 18 23. Jul 18 3,783 €146.25 €553,255
20. Jul 18 Sell Societe Generale Group, Banking Investments Company 19. Jul 18 19. Jul 18 -14,967 €149.38 €-2,235,839
20. Jul 18 Buy Societe Generale Group, Banking Investments Company 19. Jul 18 19. Jul 18 28,926 €149.21 €4,316,052
19. Jul 18 Sell Societe Generale Group, Banking Investments Company 18. Jul 18 18. Jul 18 -2,166 €148.65 €-321,976
18. Jul 18 Sell Societe Generale Group, Banking Investments Company 17. Jul 18 17. Jul 18 -9,315 €147.68 €-1,375,595
18. Jul 18 Buy Societe Generale Group, Banking Investments Company 17. Jul 18 17. Jul 18 21,708 €147.79 €3,208,187
17. Jul 18 Sell Societe Generale Group, Banking Investments Company 16. Jul 18 16. Jul 18 -924 €147.11 €-135,926
17. Jul 18 Buy Societe Generale Group, Banking Investments Company 16. Jul 18 16. Jul 18 927 €147.03 €136,300
16. Jul 18 Sell Societe Generale Group, Banking Investments Company 13. Jul 18 13. Jul 18 -3,675 €148.17 €-544,512
16. Jul 18 Buy Societe Generale Group, Banking Investments Company 13. Jul 18 13. Jul 18 1,998 €148.23 €296,164
13. Jul 18 Sell Societe Generale Group, Banking Investments Company 12. Jul 18 12. Jul 18 -3,696 €147.45 €-544,960
13. Jul 18 Buy Societe Generale Group, Banking Investments Company 12. Jul 18 12. Jul 18 13,842 €147.45 €2,040,945
12. Jul 18 Sell Societe Generale Group, Banking Investments Company 11. Jul 18 11. Jul 18 -7,809 €146.90 €-1,147,110
12. Jul 18 Buy Societe Generale Group, Banking Investments Company 11. Jul 18 11. Jul 18 16,890 €146.93 €2,481,618
04. Jul 18 Sell FMR LLC Company 03. Jul 18 03. Jul 18 -188,161 €48.29 €-9,075,823
03. Jul 18 Sell Societe Generale Group, Banking Investments Company 02. Jul 18 02. Jul 18 -2,412 €145.78 €-351,624
03. Jul 18 Buy Societe Generale Group, Banking Investments Company 02. Jul 18 02. Jul 18 2,613 €145.78 €380,926
02. Jul 18 Sell Societe Generale Group, Banking Investments Company 29. Jun 18 29. Jun 18 -8,568 €144.82 €-1,240,827
02. Jul 18 Buy Societe Generale Group, Banking Investments Company 29. Jun 18 29. Jun 18 9,495 €144.80 €1,374,852
27. Jun 18 Sell Societe Generale Group, Banking Investments Company 26. Jun 18 26. Jun 18 -17,370 €139.67 €-2,426,001
27. Jun 18 Buy Societe Generale Group, Banking Investments Company 26. Jun 18 26. Jun 18 13,785 €138.98 €1,915,900
21. Jun 18 Sell Societe Generale Group, Banking Investments Company 20. Jun 18 20. Jun 18 -13,533 €138.70 €-1,877,065
21. Jun 18 Buy Societe Generale Group, Banking Investments Company 20. Jun 18 20. Jun 18 3,477 €138.70 €482,270
22. Jun 18 Sell Societe Generale Group, Banking Investments Company 21. Jun 18 21. Jun 18 -18,144 €140.38 €-2,547,046
22. Jun 18 Buy Societe Generale Group, Banking Investments Company 21. Jun 18 21. Jun 18 11,454 €140.04 €1,604,052
18. May 18 Sell T. Rowe Price Group, Inc. Company 17. May 18 17. May 18 -300 €144.71 €-43,359
15. May 18 Sell Jean-Luc Butel Individual 14. May 18 14. May 18 -3,691 €140.97 €-520,335
15. May 18 Sell Jean-Luc Butel Individual 11. May 18 11. May 18 -3,692 €138.46 €-511,206
08. May 18 Sell T. Rowe Price Group, Inc. Company 04. May 18 04. May 18 -18,900 €132.50 €-2,502,792
08. May 18 Buy T. Rowe Price Group, Inc. Company 04. May 18 04. May 18 3 €131.53 €395
03. May 18 Sell T. Rowe Price Group, Inc. Company 02. May 18 02. May 18 -900 €131.52 €-118,366
03. May 18 Buy T. Rowe Price Group, Inc. Company 02. May 18 02. May 18 108 €131.58 €14,204
02. May 18 Sell T. Rowe Price Group, Inc. Company 01. May 18 01. May 18 -500 €132.91 €-66,452
02. May 18 Buy T. Rowe Price Group, Inc. Company 01. May 18 01. May 18 3 €132.57 €398
01. May 18 Sell T. Rowe Price Group, Inc. Company 30. Apr 18 30. Apr 18 -10,205 €131.48 €-1,341,637
01. May 18 Buy T. Rowe Price Group, Inc. Company 30. Apr 18 30. Apr 18 10 €131.39 €1,314
30. Apr 18 Sell T. Rowe Price Group, Inc. Company 27. Apr 18 27. Apr 18 -1,031 €44.35 €-45,727
27. Apr 18 Sell T. Rowe Price Group, Inc. Company 26. Apr 18 26. Apr 18 -38,133 €132.85 €-5,052,873
26. Apr 18 Sell T. Rowe Price Group, Inc. Company 25. Apr 18 25. Apr 18 -54,600 €134.61 €-7,343,461
01. May 18 Sell Societe Generale Group, Banking Investments Company 30. Apr 18 30. Apr 18 -4,485 €132.04 €-592,199
01. May 18 Buy Societe Generale Group, Banking Investments Company 30. Apr 18 30. Apr 18 3,762 €133.06 €500,566
30. Apr 18 Sell Societe Generale Group, Banking Investments Company 27. Apr 18 27. Apr 18 -14,847 €133.55 €-1,982,777
30. Apr 18 Buy Societe Generale Group, Banking Investments Company 27. Apr 18 27. Apr 18 11,367 €133.55 €1,518,032
27. Apr 18 Sell Societe Generale Group, Banking Investments Company 26. Apr 18 26. Apr 18 -4,986 €132.80 €-662,160
27. Apr 18 Buy Societe Generale Group, Banking Investments Company 26. Apr 18 26. Apr 18 17,010 €133.93 €2,278,083
26. Apr 18 Sell Societe Generale Group, Banking Investments Company 25. Apr 18 25. Apr 18 -3,003 €131.44 €-394,700
26. Apr 18 Buy Societe Generale Group, Banking Investments Company 25. Apr 18 25. Apr 18 14,103 €133.31 €1,880,019
26. Apr 18 Sell Societe Generale Group, Banking Investments Company 24. Apr 18 24. Apr 18 -40,971 €134.74 €-5,520,485
26. Apr 18 Buy Societe Generale Group, Banking Investments Company 24. Apr 18 24. Apr 18 16,233 €136.07 €2,208,774
03. Apr 18 Buy T. Rowe Price Group, Inc. Company 02. Apr 18 02. Apr 18 100 €119.50 €11,950
03. Apr 18 Sell T. Rowe Price Group, Inc. Company 29. Mar 18 29. Mar 18 -16,213 €122.72 €-1,989,664
29. Mar 18 Buy T. Rowe Price Group, Inc. Company 28. Mar 18 28. Mar 18 46,800 €123.88 €5,797,351
X
Management checks
We assess Shire's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Shire has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Company Info

Map
Description

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company’s marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Details
Name: Shire plc
SP2
Exchange: DB
Founded: 1986
£47,535,332,640
910,983,206
Website: http://www.shire.com
Address: Shire plc
Miesian Plaza,
Blocks 2 and 3,
Dublin,
Co. Dublin, 2,
Ireland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
LSE SHP Ordinary Shares London Stock Exchange GB GBP 15. Feb 1996
OTCPK SHPG.F Ordinary Shares Pink Sheets LLC US USD 15. Feb 1996
DB S7E Ordinary Shares Deutsche Boerse AG DE EUR 15. Feb 1996
NasdaqGS SHPG ADR EACH REPR 3 ORD Nasdaq Global Select US USD 25. Mar 1998
DB SP2 ADR EACH REPR 3 ORD Deutsche Boerse AG DE EUR 25. Mar 1998
LSE 0L60 ADR EACH REPR 3 ORD London Stock Exchange GB USD 25. Mar 1998
WBAG SHPG ADR EACH REPR 3 ORD Wiener Boerse AG AT EUR 25. Mar 1998
BMV SHPG N ADR EACH REPR 3 ORD Bolsa Mexicana de Valores MX MXN 25. Mar 1998
Number of employees
Current staff
Staff numbers
23,044
Shire employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/01/16 22:21
End of day share price update: 2019/01/04 00:00
Last estimates confirmation: 2019/01/04
Last earnings filing: 2018/11/01
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.